oxybutynin has been researched along with Apnea, Obstructive Sleep in 16 studies
oxybutynin: RN given refers to parent cpd
oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The combination of atomoxetine and oxybutynin for the treatment of obstructive sleep apnea in children with Down syndrome." | 9.69 | The combination of atomoxetine and oxybutynin for the treatment of obstructive sleep apnea in children with Down syndrome. ( Bottrill, K; Combs, D; Edgin, J; Gerken, B; Hsu, CH; La Rue, S; Matloff, D; Parthasarathy, S; Van Vorce, H, 2023) |
| " The combination of atomoxetine and oxybutynin for the treatment of obstructive sleep apnea in children with Down syndrome." | 5.69 | The combination of atomoxetine and oxybutynin for the treatment of obstructive sleep apnea in children with Down syndrome. ( Bottrill, K; Combs, D; Edgin, J; Gerken, B; Hsu, CH; La Rue, S; Matloff, D; Parthasarathy, S; Van Vorce, H, 2023) |
| "Ato-Trazo has the potential to become a useful drug combination, however, longer trials are needed to determine the best dosage and the subgroup of patients who may benefit most from this combination." | 3.30 | Effects of atomoxetine plus a hypnotic on obstructive sleep apnea severity in patients with a moderately collapsible pharyngeal airway. ( Corser, B; Eves, E; Rucosky, G; Warren-McCormick, J, 2023) |
| "Although recent investigations combining noradrenergic and antimuscarinic drugs have shown promising short-term results to treat obstructive sleep apnea (OSA), the mid-term effect and optimal dosage remain uncertain." | 3.30 | Effect of oxybutynin and reboxetine on obstructive sleep apnea: a randomized, placebo-controlled, double-blind, crossover trial. ( Bayon, V; Berger, M; Bradley, B; Dussez, R; Haba-Rubio, J; Heiniger, G; Heinzer, R; Lecciso, G; Marchi, NA; Siclari, F; Solelhac, G; Van Den Broecke, S, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (25.00) | 24.3611 |
| 2020's | 12 (75.00) | 2.80 |
| Authors | Studies |
|---|---|
| Perger, E | 2 |
| Taranto Montemurro, L | 1 |
| Rosa, D | 2 |
| Vicini, S | 2 |
| Marconi, M | 1 |
| Zanotti, L | 1 |
| Meriggi, P | 2 |
| Azarbarzin, A | 4 |
| Sands, SA | 4 |
| Wellman, A | 3 |
| Lombardi, C | 2 |
| Parati, G | 2 |
| Schweitzer, PK | 1 |
| Maynard, JP | 1 |
| Wylie, PE | 1 |
| Emsellem, HA | 1 |
| Kinouchi, T | 1 |
| Terada, J | 1 |
| Sakao, S | 1 |
| Koshikawa, K | 1 |
| Sasaki, T | 1 |
| Sugiyama, A | 1 |
| Sato, S | 1 |
| Sakuma, N | 1 |
| Abe, M | 1 |
| Shikano, K | 1 |
| Hayama, N | 1 |
| Shiko, Y | 1 |
| Ozawa, Y | 1 |
| Ikeda, S | 1 |
| Suzuki, T | 1 |
| Tatsumi, K | 1 |
| Edwards, BA | 1 |
| Joosten, SA | 1 |
| Corser, B | 1 |
| Eves, E | 1 |
| Warren-McCormick, J | 1 |
| Rucosky, G | 1 |
| Castiglioni, P | 1 |
| Faini, A | 1 |
| Soranna, D | 1 |
| Zambon, A | 1 |
| Pini, L | 1 |
| Baratto, C | 1 |
| Caravita, S | 1 |
| Berger, M | 1 |
| Solelhac, G | 1 |
| Marchi, NA | 1 |
| Dussez, R | 1 |
| Bradley, B | 1 |
| Lecciso, G | 1 |
| Heiniger, G | 1 |
| Bayon, V | 1 |
| Van Den Broecke, S | 1 |
| Haba-Rubio, J | 1 |
| Siclari, F | 1 |
| Heinzer, R | 1 |
| Combs, D | 1 |
| Edgin, J | 1 |
| Hsu, CH | 1 |
| Bottrill, K | 1 |
| Van Vorce, H | 1 |
| Gerken, B | 1 |
| Matloff, D | 1 |
| La Rue, S | 1 |
| Parthasarathy, S | 1 |
| Taranto-Montemurro, L | 3 |
| Messineo, L | 2 |
| Vena, D | 1 |
| Hess, LB | 1 |
| Calianese, NA | 1 |
| White, DP | 1 |
| Lavigne, G | 1 |
| Herrero Babiloni, A | 1 |
| Fabbro, CD | 1 |
| Mayer, P | 1 |
| Chen, TY | 1 |
| Chung, CH | 1 |
| Chang, HA | 1 |
| Kao, YC | 1 |
| Chang, SY | 1 |
| Kuo, TBJ | 1 |
| Yang, CCH | 1 |
| Chien, WC | 1 |
| Tzeng, NS | 1 |
| Carter, SG | 1 |
| Chiang, A | 1 |
| Vakulin, A | 1 |
| Adams, RJ | 1 |
| Carberry, JC | 1 |
| Eckert, DJ | 1 |
| Wadman, M | 1 |
| Fleury Curado, T | 1 |
| Berger, S | 1 |
| Polotsky, VY | 1 |
| Patel, SR | 1 |
| Althouse, AD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Reboxetine for Obstructive Sleep Apnoea After Upper Airway Surgery: a Randomised, Double-blind, Placebo-controlled Study[NCT05978505] | Phase 2 | 20 participants (Anticipated) | Interventional | 2023-08-15 | Not yet recruiting | ||
| Crossover, Double-blind, Phase 2 Study of AD128 Versus Placebo in Obstructive Sleep Apnea[NCT04449133] | Phase 2 | 20 participants (Actual) | Interventional | 2020-07-03 | Completed | ||
| Phase 2, Randomized, 3-Period, Placebo-Controlled Crossover Study to Evaluate the Efficacy and Safety in Obstructive Sleep Apnea of AD036 Versus Placebo or Atomoxetine[NCT04445688] | Phase 2 | 62 participants (Actual) | Interventional | 2020-07-15 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Apnea-Hypopnea Index(Disease severity is often defined based on the number of apneas and hypopneas per hour during sleep), AD036 vs. placebo (NCT04445688)
Timeframe: 1 day
| Intervention | events/hour (Least Squares Mean) |
|---|---|
| AD036 | 11.5 |
| Atomoxetine | 11.5 |
| Placebo | 18.8 |
Hypoxic burden (a way to measure oxygen desaturation) determined by measuring the respiratory event-associated area under the desaturation curve from pre-event baseline, AD036 vs. placebo. Hypoxic Burden was measured during polysomnography (type of sleep study), while the patient was asleep (NCT04445688)
Timeframe: 1 day
| Intervention | %min/hour (Least Squares Mean) |
|---|---|
| AD036 | 24.3 |
| Atomoxetine | 26.8 |
| Placebo | 46.1 |
Oxygen Desaturation Index, measured by pulse-oximetry, AD036 vs. placebo (NCT04445688)
Timeframe: 1 day
| Intervention | events/hour (Least Squares Mean) |
|---|---|
| AD036 | 12.8 |
| Atomoxetine | 13.3 |
| Placebo | 20.1 |
9 trials available for oxybutynin and Apnea, Obstructive Sleep
| Article | Year |
|---|---|
Reboxetine Plus Oxybutynin for OSA Treatment: A 1-Week, Randomized, Placebo-Controlled, Double-Blind Crossover Trial.
Topics: Adrenergic Uptake Inhibitors; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Fe | 2022 |
Reboxetine Plus Oxybutynin for OSA Treatment: A 1-Week, Randomized, Placebo-Controlled, Double-Blind Crossover Trial.
Topics: Adrenergic Uptake Inhibitors; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Fe | 2022 |
Reboxetine Plus Oxybutynin for OSA Treatment: A 1-Week, Randomized, Placebo-Controlled, Double-Blind Crossover Trial.
Topics: Adrenergic Uptake Inhibitors; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Fe | 2022 |
Reboxetine Plus Oxybutynin for OSA Treatment: A 1-Week, Randomized, Placebo-Controlled, Double-Blind Crossover Trial.
Topics: Adrenergic Uptake Inhibitors; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Fe | 2022 |
Efficacy of atomoxetine plus oxybutynin in the treatment of obstructive sleep apnea with moderate pharyngeal collapsibility.
Topics: Atomoxetine Hydrochloride; Cross-Over Studies; Humans; Sleep; Sleep Apnea, Obstructive | 2023 |
Effects of the combination of atomoxetine and oxybutynin in Japanese patients with obstructive sleep apnoea: A randomized controlled crossover trial.
Topics: Atomoxetine Hydrochloride; Cross-Over Studies; East Asian People; Humans; Oxygen; Prospective Studie | 2023 |
Effects of atomoxetine plus a hypnotic on obstructive sleep apnea severity in patients with a moderately collapsible pharyngeal airway.
Topics: Atomoxetine Hydrochloride; Humans; Hypnotics and Sedatives; Pharynx; Sleep Apnea, Obstructive | 2023 |
Impact of reboxetine plus oxybutynin treatment for obstructive sleep apnea on cardiovascular autonomic modulation.
Topics: Autonomic Nervous System; Blood Pressure Monitoring, Ambulatory; Heart Rate; Humans; Middle Aged; Re | 2023 |
Effect of oxybutynin and reboxetine on obstructive sleep apnea: a randomized, placebo-controlled, double-blind, crossover trial.
Topics: Cross-Over Studies; Double-Blind Method; Humans; Male; Oxygen; Reboxetine; Sleep Apnea, Obstructive | 2023 |
The combination of atomoxetine and oxybutynin for the treatment of obstructive sleep apnea in children with Down syndrome.
Topics: Atomoxetine Hydrochloride; Child; Down Syndrome; Humans; Quality of Life; Sleep Apnea, Obstructive; | 2023 |
Effects of the Combination of Atomoxetine and Oxybutynin on OSA Endotypic Traits.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Continuous Positive Airway Pressure; Cross- | 2020 |
Addition of zolpidem to combination therapy with atomoxetine-oxybutynin increases sleep efficiency and the respiratory arousal threshold in obstructive sleep apnoea: A randomized trial.
Topics: Arousal; Atomoxetine Hydrochloride; Humans; Mandelic Acids; Sleep; Sleep Apnea, Obstructive; Zolpide | 2021 |
7 other studies available for oxybutynin and Apnea, Obstructive Sleep
| Article | Year |
|---|---|
Variability in the response to atomoxetine and oxybutynin for OSA: Highlighting the need for personalized medicine.
Topics: Atomoxetine Hydrochloride; Humans; Precision Medicine; Sleep; Sleep Apnea, Obstructive | 2023 |
Could Atomoxetine-Oxybutynin, a Combination of Medications Being Explored for OSA Management, Have Any Effect on Sleep Bruxism or Jaw Muscle Tone?
Topics: Atomoxetine Hydrochloride; Humans; Mandelic Acids; Muscle Tonus; Sleep Apnea, Obstructive; Sleep Bru | 2021 |
Long-term atomoxetine-oxybutynin combination use may be beneficial for the prevention of obstructive sleep apnea.
Topics: Adolescent; Adult; Aged; Atomoxetine Hydrochloride; Child; Child, Preschool; Databases, Factual; Dru | 2021 |
Drug pair shows promise for treating sleep apnea.
Topics: Airway Obstruction; Atomoxetine Hydrochloride; Humans; Mandelic Acids; Sleep Apnea, Obstructive | 2018 |
Pharmacotherapy of Obstructive Sleep Apnea: Is Salvation Just Around a Corner?
Topics: Atomoxetine Hydrochloride; Cross-Over Studies; Double-Blind Method; Humans; Mandelic Acids; Sleep Ap | 2019 |
Reply to Patel and Althouse: Robust Methods Are Needed to Evaluate the Pharmacologic Treatment of Obstructive Sleep Apnea.
Topics: Atomoxetine Hydrochloride; Cross-Over Studies; Double-Blind Method; Humans; Mandelic Acids; Sleep Ap | 2019 |
Robust Methods Are Needed to Evaluate the Pharmacologic Treatment of Obstructive Sleep Apnea.
Topics: Atomoxetine Hydrochloride; Cross-Over Studies; Double-Blind Method; Humans; Mandelic Acids; Sleep Ap | 2019 |